Investor Presentation

Systemic Sclerosis Program Overview Our most advanced program with potential commercialization in 2021 20 X Positive Phase 2 results FDA EUROPEAN MEDICINES AGENCY SCIENCE MEDICINES HEALTH ‒‒‒‒-- ‒‒‒‒‒‒‒‒‒ ---- ‒‒‒‒I Ongoing open-label extension: 18 months+ (longest dosed patient > two years) Orphan Drug Designation Lenabasum Ongoing Phase 3 RESOLVE-1 study with results expected 2020 FDA Fast Track Status

View entire presentation